4. Issues of Ethnopharmacology in HIV Management
Sensitivity of HIV Tests
Initial tests for HIV infection typically employ an enzyme immunoassay (EIA) or enzyme-linked immunoassay (ELISA) antibody test or a rapid antibody test. [Holguin 2009] In contrast to earlier versions of such assays, the currently used ones detect both HIV antibodies and antigens simultaneously. [Weber 2005] The World Health Organization (WHO) recommends that these assays should have an accuracy rate of 99%, although this may vary slightly between the brands of tests.[WHO guidance, Malm 2009, Pumarola 2010] Moreover, current EIA tests can detect both HIV-1 and HIV-2. [Ciccaglione 2010] Although most HIV infections belong to HIV-1 group M, EIA tests are also able to detect infections from rare clades and groups.
However, because HIV-2 and HIV-1 group O infections are very rare in most regions, routine screening tests may not be able to detect those. [WHO HIV assays 2009] Practitioners who have reason to suspect the presence HIV-2, HIV-1 group O, or one of the rarer clades from group M should seek specialized consultation regarding diagnosis and treatment.
Treatment Considerations for Various Group and Clade Infections
Although most current antiretroviral agents were developed for use against HIV-1 clade B infections, there is no clear evidence that they are less effective against infections with viruses from other clades. However, patients infected with viruses from some clades may be more likely to develop resistance to particular antiretrovirals, and the types of resistance-associated mutations may vary. [Parkin 2004, Martinez-Cajas 2008]
However, some HIV RNA (ie, viral load) assays are sensitive only to clade B viruses and can result in significant under-reporting of a patient’s HIV RNA level when used to test samples of infections from other clades.[Holguín 2008, Rouet 2007] The most up-to-date assays claim to yield accurate results for most viruses from group M clades, with the possible exception of group O. Practitioners should endeavor to determine which clade or CRF is being assayed in a particular patient and should be aware of the limitations of the assay being used.
Not all of the agents used to treat HIV-1 infections are equally effective against infections with HIV-2.[Gottlieb 2008] For example, HIV-2 infections typically are resistant to treatment with non-nucleoside reverse transcriptase inhibitors (NNRTIs), and use of agents from this class of antiretrovirals is not recommended in patients with HIV-2 infection. Currently, the US Food and Drug Administration has not licensed a viral load assay for HIV-2 and those designed for HIV-1 are not reliable for monitoring HIV-2 RNA level. For patients with HIV-2 infection, treatment response is typically monitored by following CD4+ cell counts and other indicators of immune system function. [Peterson 2011]
The CDC cautions that the 166 HIV-2 infections identified in the United States are likely to be an underestimate of the actual number of HIV-2 cases in this country, largely due to issues surrounding the sensitivity of the diagnostic assays used in some settings.[HIV-2 Surveillance] Nevertheless, the extent of HIV-2 infection in the United States remains quite limited, with approximately two-thirds of known cases located in the Northeast. Clinicians who are managing a patient known to be infected with HIV-2 should become familiar not only with treatment recommendations for such individuals [Ntemgwa 2009, DHHS Guidelines 2011, Peterson 2011] but also should attempt to learn about any culturally specific beliefs or practices characteristic of the patient’s country or origin that could affect the provision of and adherence to HAART.